Acquired pure red cell aplasia: Updated review of treatment

172Citations
Citations of this article
124Readers
Mendeley users who have this article in their library.
Get full text

Abstract

Pure red cell aplasia (PRCA) is a syndrome characterized by a severe normocytic anaemia, reticulocytopenia, and absence of erythroblasts from an otherwise normal bone marrow. Primary PRCA, or secondary PRCA which has not responded to treatment of the underlying disease, is treated as an immunologically-mediated disease. Although vigorous immunosuppressive treatments induce and maintain remissions in a majority of patients, they carry an increased risk of serious complications. Corticosteroids were used in the treatment of PRCA and this has been considered the treatment of first choice although relapse is not uncommon. Cyclosporine A (CsA) has become established as one of the leading drugs for treatment of PRCA. However, common concerns have been the number of patients treated with CsA who achieve sustained remissions and the number that relapse. This article reviews the current status of CsA therapy and compares it to other treatments for diverse PRCAs. © 2008 The Authors.

Cite

CITATION STYLE

APA

Sawada, K., Fujishima, N., & Hirokawa, M. (2008, August). Acquired pure red cell aplasia: Updated review of treatment. British Journal of Haematology. https://doi.org/10.1111/j.1365-2141.2008.07216.x

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free